Outcomes of Micropulse Transscleral Cyclophotocoagulation in Eyes With Good Central Vision

医学 眼压 青光眼 眼科 视力 青光眼药物治疗 回顾性队列研究 激光凝固 青光眼手术 外科
作者
Venkata N.V. Varikuti,Parth Shah,Oshin Rai,Ariel Chaves,Alex Miranda,Bee Jik Lim,Syril Dorairaj,Sandra Sieminski
出处
期刊:Journal of Glaucoma [Lippincott Williams & Wilkins]
卷期号:28 (10): 901-905 被引量:65
标识
DOI:10.1097/ijg.0000000000001339
摘要

This study is the first to report micropulse transscleral cyclophotocoagulation (MP-TSCPC) use in only good vision patients. MP-TSCPC significantly reduced intraocular pressure (IOP) and glaucoma medication use without any significant reduction in visual acuity at every postoperative follow-up point.To evaluate outcomes of MP-TSCPC in eyes with baseline best-corrected visual acuity (BCVA) of ≥20/60.A retrospective review of patients who underwent MP-TSCPC at Mayo Clinic and Ross Eye Institute from July 2016 to August 2017 with BCVA of ≥20/60, and a minimum of 3 months follow-up.A total of 61 eyes of 46 patients (68.80±17.12 y) underwent MP-TSCPC with a mean follow-up of 10.2±3.1 months. Mean IOP and mean number of glaucoma medications used were significantly reduced from baseline at every follow-up time point (P<0.0001). At month 12, mean IOP was reduced 40.2% from baseline with 85.4% of the patients having an IOP reduction of ≥20%, and mean glaucoma medication use reduced by 0.82±0.53 with 79.6% of the patients having a reduction of ≥1 medication. There was no significant reduction in BCVA from baseline at any follow-up point (P>0.05), except for 10 eyes with a vision loss of ≥2 lines and 5 out of 10 eyes had cataract progression. The probability of complete success (IOP range, 6 to 21 mm Hg or ≥20% IOP reduction; BCVA loss ≤2 lines, no reoperation for glaucoma) was 74.14%, 83.61%, 84.21%, and 75.0% at months 1, 3, 6, 12, respectively. The probability of qualified success (above criteria for IOP, no reoperation and BCVA loss >2 lines) was 81.03%, 91.80%, 94.74%, and 93.75% at months 1, 3, 6, 12, respectively.MP-TSCPC should be considered earlier in the management of glaucoma and can possibly be offered as an alternative to incisional glaucoma surgeries.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文败类的应助被Leoitch采纳,获得10
刚刚
刚刚
慕青的应助被夏夏采纳,获得10
1秒前
Owen的应助被开放如天采纳,获得10
1秒前
沉淀完成签到,获得积分10
1秒前
舒服的尔曼完成签到,获得积分10
1秒前
嘟嘟嘟嘟发布了新的文献求助30
1秒前
han完成签到,获得积分10
2秒前
45275357完成签到 ,获得积分10
2秒前
顺心的鸽子完成签到,获得积分10
3秒前
司空悒完成签到,获得积分0
3秒前
4秒前
小二郎的应助被sanger采纳,获得10
4秒前
JJZ完成签到,获得积分10
4秒前
369ninja发布了新的文献求助10
4秒前
隐形曼青的应助被虚拟的访曼采纳,获得10
5秒前
xiaojin完成签到,获得积分10
5秒前
DW的应助被张博采纳,获得10
5秒前
Youdge的应助被巴拉巴拉采纳,获得20
5秒前
情怀的应助被liuliu采纳,获得10
6秒前
AAA建材批发王总完成签到 ,获得积分10
6秒前
小面包发布了新的文献求助30
6秒前
7秒前
Akim的应助被自由的藏鸟采纳,获得10
7秒前
CGFHEMAN完成签到 ,获得积分10
7秒前
大力的安青完成签到,获得积分10
7秒前
8秒前
今后的应助被叫你吃布丁采纳,获得10
8秒前
8秒前
开朗灵寒完成签到,获得积分10
8秒前
林寒191065完成签到 ,获得积分10
8秒前
科研通AI6.3的应助被苗子采纳,获得10
8秒前
9秒前
S01完成签到,获得积分10
9秒前
wwwwwl发布了新的文献求助30
9秒前
拼搏草莓发布了新的文献求助10
9秒前
情怀的应助被Nora采纳,获得10
10秒前
我是老大的应助被Nora采纳,获得10
10秒前
科目三的应助被Nora采纳,获得10
10秒前
现代的芹完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460